Key Takeaways
- • Fresenius launches Fresenius Ventures, a new corporate venture capital fund with €200 million+ investment capacity deployed over five years (2026–2031), targeting healthcare innovation adjacent to its core platforms.
- • The fund will invest across precision nutrition, microbiome research, new modalities, and digital care provision solutions, complementing Fresenius' existing (Bio)Pharma, MedTech, and Care Provision strategic platforms.
- • Dr. Thomas Michael Thestrup, former leader at Angelini Ventures, heads the new unit, bringing healthcare and corporate venture capital expertise to combine deal-making with medical, regulatory, and operational resources.
- • Fresenius Ventures will invest from early-stage financing through growth stage, providing portfolio companies access to clinical, scientific, and academic networks alongside capital deployment aligned with Fresenius' capital allocation framework.
- • CEO Michael Sen positions the fund as a strategic instrument of #FutureFresenius, designed to secure early-stage access to breakthrough technologies, entrepreneurial talent, and adjacent growth fields while strengthening core business capabilities.
Summary
Fresenius, the global healthcare conglomerate, has established Fresenius Ventures, a corporate venture capital fund targeting €200 million in investments over five years commencing July 2026. The initiative represents an expansion of the company's innovation strategy, enabling direct participation in early-to-growth stage healthcare technologies and business models outside its immediate operating portfolio.
The fund's investment mandate spans growth fields adjacent to Fresenius' three core strategic platforms: (Bio)Pharma, MedTech, and Care Provision. Specific focus areas include precision nutrition, microbiome research, new modalities, and digital care provision solutions. By structuring the fund around adjacency to existing platforms, Fresenius aims to capture innovation opportunities that leverage its clinical networks, regulatory expertise, and operational infrastructure while maintaining disciplined capital allocation consistent with group-level investment policy.
Dr. Thomas Michael Thestrup, recruited from Angelini Ventures—an international healthcare venture capital platform within the Italian industrial conglomerate Angelini Industries—will lead Fresenius Ventures. The appointment underscores the company's intent to pair venture capital expertise with deep healthcare domain knowledge. According to Michael Sen, Fresenius CEO, the fund serves as a strategic instrument of the company's #FutureFresenius transformation agenda, designed to provide early access to breakthrough technologies, emerging entrepreneurial talent, and adjacent growth opportunities while systematically strengthening core business capabilities.
The venture capital unit differentiates itself by combining capital deployment with medical, regulatory, and operational expertise, alongside access to clinical, scientific, and academic networks. This hybrid model positions Fresenius Ventures to support portfolio companies beyond traditional financing, addressing the execution and commercialization challenges that early-stage healthcare innovators often face. Investments will span from seed and early financing rounds through growth-stage capital raises, aligning with founder expectations for both pace and conviction in healthcare venture investing.
The fund's investment mandate spans growth fields adjacent to Fresenius' three core strategic platforms: (Bio)Pharma, MedTech, and Care Provision. Specific focus areas include precision nutrition, microbiome research, new modalities, and digital care provision solutions. By structuring the fund around adjacency to existing platforms, Fresenius aims to capture innovation opportunities that leverage its clinical networks, regulatory expertise, and operational infrastructure while maintaining disciplined capital allocation consistent with group-level investment policy.
Dr. Thomas Michael Thestrup, recruited from Angelini Ventures—an international healthcare venture capital platform within the Italian industrial conglomerate Angelini Industries—will lead Fresenius Ventures. The appointment underscores the company's intent to pair venture capital expertise with deep healthcare domain knowledge. According to Michael Sen, Fresenius CEO, the fund serves as a strategic instrument of the company's #FutureFresenius transformation agenda, designed to provide early access to breakthrough technologies, emerging entrepreneurial talent, and adjacent growth opportunities while systematically strengthening core business capabilities.
The venture capital unit differentiates itself by combining capital deployment with medical, regulatory, and operational expertise, alongside access to clinical, scientific, and academic networks. This hybrid model positions Fresenius Ventures to support portfolio companies beyond traditional financing, addressing the execution and commercialization challenges that early-stage healthcare innovators often face. Investments will span from seed and early financing rounds through growth-stage capital raises, aligning with founder expectations for both pace and conviction in healthcare venture investing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.